Response to ImmunoGen's Mirvetuximab Soravtansine Found to be Substantially Greater in Ovarian Cancer with High Expression of Folate Receptor Alpha

ImmunoGen, Inc.

today reported findings with mirvetuximab soravtansine, its novel folate receptor alpha (FRα)-targeting ADC product candidate, being presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (abstract #C47). Analysis of the association between the amount of FRα present on patient cancer cells and response to treatment with mirvetuximab soravtansine found nine of ten (90%) patients with high levels of FRα had an objective response on treatment. "These early findings are highly encouraging as they underscore the potential of mirvetuximab soravtansine to make an important difference